top of page
News, Events and Updates
Search
May 3, 2010
Anavex Reports Animal Study Results as Lead Alzheimer’s Compound Approaches Phase 1 Clinical Trials
Mar 3, 2010
Anavex Comments on Failure of Pfizer and Medivation’s Dimebon
Jan 18, 2010
Anavex Appoints Dr. Cameron Durrant Executive Chairman of the Board
Sep 29, 2009
Anavex Contracts FORENAP Pharma for Pre-Clinical Trials of ANAVEX 2-73 in Alzheimer's Disease
Sep 20, 2009
Anavex Completes Scale-Up Manufacturing of ANAVEX 2-73 for Phase I AD Clinical Trials
Aug 26, 2009
Anavex Reports Sigma Receptor Review Published in Leading Journal
Jun 15, 2009
ANAVEX Appoints Dr. Hervé de Kegrohen as CEO to Lead Company Through Clinical Trials & Future Growth
Apr 7, 2009
Pharmawire: Medivation, Anavex May Lower Oxidative Stress
Feb 10, 2009
Anavex Appoints Leading Alzheimer’s Disease Expert Dr. Mark Smith to Scientific Advisory Board
Jan 30, 2009
Anavex Scales Up Synthesis of ANAVEX 2-73 for Phase 1 Alzheimer’s Disease Study
Dec 17, 2008
Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer’s Compound ANAVEX 1-41
45
46
47
48
49
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
